[Viewpoint of the German Dermatologic Society (DDG) concerning the decision of the American Food and Drug Administration (FDA) on the use of pimecrolimus cream and tacrolimus ointment in the treatment of atopic dermatitis (neurodermatitis)].
Luger
Thomas A
TA
Gollnick
Harald
H
D003876:Dermatitis, Atopic / Q000188:drug therapy*; D003879:Dermatologic Agents / Q000008:administration & dosage*; D003880:Dermatology; D005858:Germany; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D009824:Ointments; D012955:Societies, Medical; D016559:Tacrolimus / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D014481:United States; D014486:United States Food and Drug Administration
D003879:Dermatologic Agents; D007166:Immunosuppressive Agents; D009824:Ointments; C117268:pimecrolimus; D016559:Tacrolimus